Stock AMGN34 AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Delayed Sao Paulo
Other stock markets
 03:18:13 2024-06-19 pm EDT 		5-day change 1st Jan Change
58.56 BRL +18.33% Intraday chart for Amgen Inc. +2.34% +17.24%
Jun. 14 Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto DJ
Jun. 14 Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto
DJ
Amgen : Continues to Propel BiTE® Technology Innovation
PU
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer
MT
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
PR
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto
CI
Sector Update: Health Care Stocks Softer Friday Afternoon
MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating
MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating
MT
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%
MT
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
PR
Amgen : Leaders Hail Southern California’s Emergence as Biotech Innovation Hub
PU
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation
AQ
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar
AQ
Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab
AQ
AbbVie's tight grip on Humira market raises concerns about biosimilars
RE
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE
AQ
Transcript : Amgen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. AMGN34 Stock
  5. News Amgen Inc.